Rafferty Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-180,471
| Closed | -$7.26M | – | 1137 |
|
|
2026
Q1 | $7.26M | Buy |
180,471
+9,015
| +5% | +$194K | 0.03% | 293 |
|
|
2025
Q4 | $4.31M | Buy |
171,456
+3,104
| +2% | +$72.8K | 0.01% | 473 |
|
|
2025
Q3 | $3.81M | Buy |
168,352
+24,500
| +17% | +$571K | 0.01% | 496 |
|
|
2025
Q2 | $2.49M | Sell |
143,852
-36,282
| -20% | -$672K | 0.01% | 552 |
|
|
2025
Q1 | $3.94M | Sell |
180,134
-61,340
| -25% | -$1.69M | 0.02% | 420 |
|
|
2024
Q4 | $7.71M | Buy |
241,474
+37,328
| +18% | +$1.12M | 0.03% | 328 |
|
|
2024
Q3 | $5.89M | Sell |
204,146
-37,836
| -16% | -$1.4M | 0.02% | 388 |
|
|
2024
Q2 | $9.28M | Buy |
241,982
+93,181
| +63% | +$4.22M | 0.03% | 295 |
|
|
2024
Q1 | $8.75M | Buy |
148,801
+5,683
| +4% | +$362K | 0.03% | 318 |
|
|
2023
Q4 | $8.57M | Sell |
143,118
-71,043
| -33% | -$3.6M | 0.04% | 321 |
|
|
2023
Q3 | $8.15M | Buy |
214,161
+121,893
| +132% | +$5.35M | 0.05% | 281 |
|
|
2023
Q2 | $8.41M | Sell |
92,268
-17,130
| -16% | -$1.48M | 0.05% | 250 |
|
|
2023
Q1 | $7.22M | Sell |
109,398
-54,706
| -33% | -$3.16M | 0.05% | 282 |
|
|
2022
Q4 | $8.49M | Buy |
164,104
+61,532
| +60% | +$3.26M | 0.07% | 236 |
|
|
2022
Q3 | $7.01M | Buy |
102,572
+9,683
| +10% | +$573K | 0.07% | 220 |
|
|
2022
Q2 | $4.2M | Sell |
92,889
-30,606
| -25% | -$1.4M | 0.04% | 311 |
|
|
2022
Q1 | $6.28M | Sell |
123,495
-2,415
| -2% | -$107K | 0.04% | 315 |
|
|
2021
Q4 | $5.95M | Buy |
125,910
+36,711
| +41% | +$1.45M | 0.03% | 307 |
|
|
2021
Q3 | $2.94M | Buy |
89,199
+47,208
| +112% | +$2.65M | 0.02% | 488 |
|
|
2021
Q2 | $2.65M | Sell |
41,991
-29,421
| -41% | -$1.52M | 0.02% | 554 |
|
|
2021
Q1 | $3.06M | Buy |
71,412
+52,653
| +281% | +$2.49M | 0.02% | 478 |
|
|
2020
Q4 | $1.07M | Sell |
18,759
-50,470
| -73% | -$2.13M | 0.01% | 482 |
|
|
2020
Q3 | $2.09M | Buy |
69,229
+38,410
| +125% | +$1.15M | 0.03% | 401 |
|
|
2020
Q2 | $1.01M | Buy |
30,819
+22,557
| +273% | +$724K | 0.01% | 540 |
|
|
2020
Q1 | $221K | Sell |
8,262
-61,996
| -88% | -$2.2M | 0.01% | 501 |
|
|
2019
Q4 | $2.15M | Buy |
70,258
+10,579
| +18% | +$293K | 0.03% | 363 |
|
|
2019
Q3 | $1.44M | Sell |
59,679
-5,124
| -8% | -$141K | 0.02% | 465 |
|
|
2019
Q2 | $1.64M | Buy |
64,803
+37,450
| +137% | +$762K | 0.03% | 463 |
|
|
2019
Q1 | $533K | Buy |
+27,353
| New | +$430K | 0.01% | 656 |
|
Other funds holding APLS
Rafferty Asset Management's APLS Position: Q2 2026 in Review
Rafferty Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 180,471 shares — an estimated $7.26M sold.
Rafferty Asset Management first reported a position in APLS in Q1 2019 and held it in 29 quarters. The position peaked at $9.28M in Q2 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Rafferty Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Rafferty Asset Management sold 180,471 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.26M.
- Rafferty Asset Management first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 29 quarters.
- Rafferty Asset Management's Apellis Pharmaceuticals position peaked at $9.28M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.